COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01966055
Recruitment Status : Completed
First Posted : October 21, 2013
Last Update Posted : February 23, 2017
Department of Health and Human Services
Information provided by (Responsible Party):
Melinta Therapeutics, Inc.

Brief Summary:
A study of the safety and pharmacokinetics of solithromycin capsules in adolescents

Condition or disease Intervention/treatment Phase
Bacterial Infections Drug: Solithromycin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Multi-center Study to Determine the PK and Safety of Solithromycin as Add-on Therapy in Adolescents With Suspected or Confirmed Bacterial Infection
Study Start Date : December 2013
Actual Primary Completion Date : August 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Solithromycin Drug: Solithromycin

Primary Outcome Measures :
  1. Area under the plasma concentration versus time curve (AUC) of solithromycin in adolescents [ Time Frame: 5 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 12 to 17 yo male or female with suspected or confirmed bacterial infection

Exclusion Criteria:

  • Bacterial meningitis
  • Clinical significant concomitant medical condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01966055

Layout table for location information
United States, Arkansas
Little Rock, Arkansas, United States, 72202
United States, California
San Diego, California, United States, 92123
United States, Illinois
Chicago, Illinois, United States, 60611
United States, Kentucky
Louisville, Kentucky, United States, 40202
United States, Michigan
Ann Arbor, Michigan, United States, 48109
United States, New Jersey
Hackensack, New Jersey, United States, 07601
United States, New York
New York, New York, United States, 10032
United States, Oregon
Portland, Oregon, United States, 97239
United States, Pennsylvania
Hershey, Pennsylvania, United States, 17033
United States, Texas
Galveston, Texas, United States, 77555-0701
Houston, Texas, United States, 77030
Sponsors and Collaborators
Melinta Therapeutics, Inc.
Department of Health and Human Services
Layout table for investigator information
Principal Investigator: Michael Cohen-Wolkowiez, MD Duke Clinical Research Institute

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Melinta Therapeutics, Inc. Identifier: NCT01966055    
Other Study ID Numbers: CE01-119
First Posted: October 21, 2013    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents